Acrux Ltd
ASX:ACR

Watchlist Manager
Acrux Ltd Logo
Acrux Ltd
ASX:ACR
Watchlist
Price: 0.015 AUD 7.14%
Market Cap: 6.1m AUD

Operating Margin
Acrux Ltd

-156%
Current
-99%
Average
6.5%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-156%
=
Operating Profit
-6.3m
/
Revenue
4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Acrux Ltd
ASX:ACR
6.1m AUD
-156%
US
Eli Lilly and Co
NYSE:LLY
660.9B USD
42%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
424.9B USD
26%
CH
Roche Holding AG
SIX:ROG
203.1B CHF
33%
UK
AstraZeneca PLC
LSE:AZN
182B GBP
24%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
46%
CH
Novartis AG
SIX:NOVN
194.2B CHF
33%
US
Merck & Co Inc
NYSE:MRK
211.9B USD
38%
IE
Endo International PLC
LSE:0Y5F
183.4B USD
11%
US
Pfizer Inc
NYSE:PFE
143B USD
29%

Acrux Ltd
Glance View

Market Cap
6.1m AUD
Industry
Pharmaceuticals

Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-29. The firm is engaged in developing and commercializing a portfolio of generic topical prescription pharmaceutical products which use dermal and transdermal drug delivery technology. The firm's product pipeline includes Evamist, Lenzetto, Jublia, EMLA and Testosterone Topical Solution. The firm's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The products offered by the Company are the testosterone topical solution to treat adult males who have low or no testosterone and Estradiol MDTS to treat moderate to severe hot flushes commonly associated with menopause. The company is also developing a range of topical and dermatological generic products for the United States market. The firm operates in the United States, Europe and other markets.

ACR Intrinsic Value
0.117 AUD
Undervaluation 87%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-156%
=
Operating Profit
-6.3m
/
Revenue
4m
What is the Operating Margin of Acrux Ltd?

Based on Acrux Ltd's most recent financial statements, the company has Operating Margin of -156%.

Back to Top